H Kinnunen
Extrinsic lactose fines improve dry powder inhaler formulation performance of a cohesive batch of budesonide via agglomerate formation and consequential co-deposition
Kinnunen, H; Hebbink, G; Peters, H; Huck, D; Makein, L; Price, R
Authors
G Hebbink
H Peters
D Huck
L Makein
R Price
Contributors
H Bown (née Kinnunen) kwmd75@durham.ac.uk
Other
Abstract
The aim of the study was to investigate how the fine particle content of lactose carriers prepared with different types of lactose fines regulates dry powder inhaler (DPI) formulation performance of a cohesive batch of micronised budesonide. Budesonide formulations (0.8 wt-% ) were prepared with three different lactose carriers (Lactohale (LH) LH100, 20 wt-% LH210 in LH100 and 20 wt-% LH300 in LH100). Fine particle fraction of emitted dose (FPFED) and mean mass aerodynamic diameter (MMAD) of budesonide was assessed with a Next Generation Impactor (NGI) using a Cyclohaler at 90 l/min. Morphological and chemical characteristics of particles deposited on Stage 2 were determined using a Malvern Morphologi G3-ID. The results indicate that increasing concentration of lactose fines (<4.5 μm) not only increased the FPFED but also the MMAD of budesonide, suggesting drug deposition in agglomerates. Presence of agglomerates on Stage 2 was confirmed by morphological analysis of particles. Raman analysis of material collected on Stage 2 indicated that the more fine lactose particles were available the more agglomerates of budesonide and lactose were delivered to the Stage 2. These results suggest drug-fines agglomerate formation is an important mechanism for how lactose fines improve and regulate DPI formulation performance.
Citation
Kinnunen, H., Hebbink, G., Peters, H., Huck, D., Makein, L., & Price, R. (2015). Extrinsic lactose fines improve dry powder inhaler formulation performance of a cohesive batch of budesonide via agglomerate formation and consequential co-deposition. International Journal of Pharmaceutics, 478(1), 53-59. https://doi.org/10.1016/j.ijpharm.2014.11.019
Journal Article Type | Article |
---|---|
Publication Date | Jan 15, 2015 |
Deposit Date | Nov 17, 2014 |
Publicly Available Date | Mar 28, 2024 |
Journal | International Journal of Pharmaceutics |
Print ISSN | 0378-5173 |
Publisher | Elsevier |
Peer Reviewed | Peer Reviewed |
Volume | 478 |
Issue | 1 |
Pages | 53-59 |
DOI | https://doi.org/10.1016/j.ijpharm.2014.11.019 |
Keywords | Lactose, Dry powder inhaler, Raman spectroscopy. |
Files
Accepted Journal Article
(397 Kb)
PDF
Copyright Statement
NOTICE: this is the author’s version of a work that was accepted for publication in International Journal of Pharmaceutics. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in International Journal of Pharmaceutics, 478, 1, 15 January 2015, 10.1016/j.ijpharm.2014.11.019.
You might also like
Downloadable Citations
About Durham Research Online (DRO)
Administrator e-mail: dro.admin@durham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search